Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 4th edition, 372 pages

+ the daily Top 10


  Bladder Cancer

  Free Subscription


Articles published in J Clin Oncol

Retrieve available abstracts of 13 articles:
HTML format



Single Articles


    May 2020
  1. WINQUIST E, Booth CM
    Trimodality Therapy for Muscle-Invasive Bladder Cancer: Concurrent Chemotherapy is Not Enough.
    J Clin Oncol. 2020 May 27:JCO1902959. doi: 10.1200/JCO.19.02959.
    PubMed    


    January 2020
  2. DE VERE WHITE R, Lara PN Jr, Black PC, Evans CP, et al
    Framing Pragmatic Strategies to Reduce Mortality From Bladder Cancer: An Endorsement From the Society of Urologic Oncology.
    J Clin Oncol. 2020 Jan 17:JCO1901731. doi: 10.1200/JCO.19.01731.
    PubMed    


    February 2019
  3. ZHANG S
    Neoadjuvant Immunotherapy in Muscle-Invasive Bladder Cancer: Time to Change Clinical Practice?
    J Clin Oncol. 2019 Feb 27:JCO1801864. doi: 10.1200/JCO.18.01864.
    PubMed    


    November 2018
  4. COEN JJ, Zhang P, Saylor PJ, Lee CT, et al
    Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial.
    J Clin Oncol. 2018 Nov 15:JCO1800537. doi: 10.1200/JCO.18.00537.
    PubMed     Abstract available


    September 2018
  5. MOSSANEN M, Caldwell J, Sonpavde G, Lehmann LS, et al
    Treating Patients With Bladder Cancer: Is There an Ethical Obligation to Include Smoking Cessation Counseling?
    J Clin Oncol. 2018 Sep 13:JCO1800577. doi: 10.1200/JCO.18.00577.
    PubMed    


    May 2018
  6. IYER G, Balar AV, Milowsky MI, Bochner BH, et al
    Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer.
    J Clin Oncol. 2018 May 9:JCO2017750158. doi: 10.1200/JCO.2017.75.0158.
    PubMed     Abstract available


    December 2017
  7. BOOTH CM, Karim S, Peng Y, Siemens DR, et al
    Radical Treatment of the Primary Tumor in Metastatic Bladder Cancer: Potentially Dangerous Findings From Observational Data.
    J Clin Oncol. 2017 Dec 13:JCO2017761759. doi: 10.1200/JCO.2017.76.1759.
    PubMed    


    August 2017
  8. SHORE ND, Boorjian SA, Canter DJ, Ogan K, et al
    Intravesical rAd-IFNalpha/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study.
    J Clin Oncol. 2017 Aug 23:JCO2017723064. doi: 10.1200/JCO.2017.72.3064.
    PubMed     Abstract available


    July 2017
  9. BALAR AV
    Immune Checkpoint Blockade in Metastatic Urothelial Cancer.
    J Clin Oncol. 2017;35:2109-2112.
    PubMed     Abstract available


    April 2017
  10. KULKARNI GS, Hermanns T, Wei Y, Bhindi B, et al
    Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.
    J Clin Oncol. 2017 Apr 14:JCO2016692327. doi: 10.1200/JCO.2016.69.2327.
    PubMed     Abstract available


    January 2017
  11. POWLES T, Huddart RA, Elliott T, Sarker SJ, et al
    Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer.
    J Clin Oncol. 2017;35:48-55.
    PubMed     Abstract available


    January 2016
  12. KUSHI LH, Quinn VP, Ghai NR, Roh JM, et al
    Identifying lifestyle and genetic factors to prevent recurrence of non-muscle invasive bladder cancer in a prospective cohort study at Kaiser Permanente (the Be-Well study).
    J Clin Oncol. 2016;34.
    PubMed     Abstract available


  13. DANFORTH KN, Kwan ML, Bulkley JE, O'Keeffe-Rosetti MC, et al
    Recovery challenges faced by bladder cancer survivors after recent cystectomy and urinary diversion.
    J Clin Oncol. 2016;34.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: